ISSN: 2583-9888
DOI: doi.org/10.51219/JAIMLD/Aditya-gadiko/71

URF PUBLISHERS
connect with research world

Journal of Artificial Intelligence, Machine Learning and Data Science

https://urfpublishers.com/journal/artificial-intelligence

Vol: 1 & Iss: 1

Clinical Study

Practical uses of AI in Contemporary Clinical Trials

Aditya Gadiko*

Citation: Aditya Gadiko. Practical uses of AI in Contemporary Clinical Trials. *J Artif Intell Mach Learn & Data Sci 2022*, 1(1), 219-221. DOI: doi.org/10.51219/JAIMLD/Aditya-gadiko/71

Received: 03 November, 2022; **Accepted:** 28 November, 2022; **Published:** 30 November, 2022

***Corresponding author:** Aditya Gadiko, Product Management, Saama Technologies, 900 East Hamilton Avenue, Campbell, 95008, CA, USA, E-mail: Aditya.Gadiko@saama.com

ABSTRACT

The landscape of clinical trials is transforming, propelled by the integration of Artificial Intelligence (AI). This paper delineates three pivotal ways AI can be leveraged to address the burgeoning challenges in clinical research. As data sources proliferate, the volume of patient data entering clinical study databases escalates, mandating a reevaluation of traditional data management strategies. Firstly, AI models are instrumental in predicting patient behaviors that significantly influence trial outcomes. Identifying and analyzing behavioral patterns enable timely interventions, which can mitigate patient dropout and non-adherence rates, potentially improving overall trial success. Secondly, AI's predictive analytics are critical in preempting clinical adverse events. By analyzing extensive historical data, AI models can anticipate adverse events, allowing clinicians to address risks and preemptively enhance patient safety within trials. Thirdly, AI contributes to the optimization of data trans- formation processes. Converting copious amounts of raw data into structured, analyzable formats is expedited through AI, reducing the resource-intensive manual burden and minimizing the likelihood of human error. This paper explores the immediate application of AI in transforming voluminous and complex clinical trial data into actionable insights. AI's capacity to swiftly process and analyze data not only streamlines clinical trials but also fortifies the decision-making process, ensuring that patient safety and trial integrity are upheld. Moreover, the adaptation of AI-driven systems for data review and management enables a significant reduction in time and resources spent on manual reviews, thereby accelerating trial timelines and aiding in the expedient delivery of therapies to patients. The paper underscores the urgency for clinical researchers to adopt AI tools as clinical trials continue to evolve. These tools present opportunities for improved efficiency and patient safety, ultimately contributing to the successful execution of clinical trials in the contemporary medical landscape.

Keywords: Clinical Trials, Artificial Intelligence, Prediction patient behaviour, Patient adherence, Patient dropouts, Adverse events, Data Patterns, SDTM

1. Introduction

In an era where digital technology seamlessly integrates into the fabric of healthcare, the paradigm of clinical trials is witnessing an unprecedented influx of patient data. The capacity to harness data from a myriad of sources has triggered an exponential increase in data points[1], each a potential catalyst for advancing medical research and patient care. Technologies that enable researchers to extend their reach globally are not only expanding the scope of data collection but are also amplifying the complexities of monitoring, formatting, and analyzing this wealth of information.

This expansion, however, unfolds against the backdrop of a global talent deficit in the clinical trials sphere[2]. The current ecosystem, strained by resource constraints, sees sponsors, Contract Research Organizations (CROs), and clinical sites in a continuous loop of talent reallocation a zero-sum game that offers no tangible solution to the underlying scarcity.

Given the impracticality of merely increasing workforce numbers to manage this data deluge, artificial intelligence (AI) emerges as a beacon of solution[3]. AI's capacity to manage vast informational volumes and streamline decision- making processes is redefining the approach to clinical trials management. Researchers are poised at the cusp of transitioning from labor-intensive manual operations to automated processes that swiftly translate data into actionable insights. This is paramount not only for maintaining patient safety and engagement but also for fortifying the integrity and efficiency of clinical trials.

This paper navigates through the labyrinth of data challenges and elucidates how AI can be pivotal in reshaping the terrain. It will unpack three critical applications of AI in clinical trials: predicting patient behaviors, identifying patterns within complex data arrays, and transforming raw data into analytical treasure troves. Each application is dissected to re- veal its potential in enhancing patient outcomes and expediting clinical processes, ultimately heralding a new dawn for clinical research methodologies.

2. Predicting Patient Behavior using AI

In the intricate landscape of clinical trials, patient adherence, dropout rates, and adverse event occurrence are critical determinants of success. Artificial intelligence (AI) emerges as an innovative ally, equipping researchers with advanced tools to swiftly detect and interpret behavior patterns related to these pivotal challenges. AI facilitates rapid adjustment and realignment of studies, ensuring steady progress in the intended direction.

Predicting patient behaviors within clinical trials necessitates sifting through copious amounts of diverse data, a task far beyond human capability for prompt analysis. AI leverages its vast computational power to parse such data, extracting actionable insights from various data types, including demographics, medical histories, treatment regimens, and technology-mediated information like wearable device metrics.

2.1. Predicting patient dropouts

The reasons for patient withdrawal from trials are multifaceted. AI serves as a sentinel, identifying subtle behavioral shifts that signal possible patient struggles or foreshadow potential dropout risks[4]. By providing early warnings, AI enables the clinical team to take proactive measures, thereby fortifying patient retention.

2.2. Enhancing patient adherence

The success of a trial hinges on patients adhering to prescribed treatments, completing ePROs, and complying with study visits and device usage. AI assists in forecasting which patients may deviate from their treatment plans, allowing early interventions to sustain adherence[5].

2.3. Anticipating adverse events

Rapid identification of adverse event risks enhances the safety profile of clinical trial participation. AI's predictive analysis can pinpoint the probability of adverse events[6], facilitating prompt and targeted monitoring, especially for patient groups stratified by age, gender, race, or origin.

2.4. Uncover data patterns using AI

Incorporating AI for these purposes not only streamlines trial management and curtails costs but also significantly contributes to elevating patient safety. AI's predictive capabilities can be harnessed to surmount common trial hurdles, enrich patient outcomes, and foster a more efficient, data-driven approach to clinical research.

The realm of clinical research is marked by the integration and analysis of data from an assortment of sources, including direct patient inputs, medical device outputs, laboratory assessments, and electronic health records, as well as the expansive domain of real-world data (RWD). The sheer volume of this data, coupled with the disparate nature of data repositories and the lack of standardized software interfaces, presents a formidable challenge in the swift extraction of actionable intelligence. Compounding this issue is the frequent occurrence of missing values, data inconsistencies, and a multiplicity of data formats that render conventional analytical techniques suboptimal.

Within this context, artificial intelligence (AI) emerges as a powerful tool for discerning complex data patterns that elude direct human observation. AI systems excel at detecting nuanced correlations[7], unveiling trends[8], and revealing latent connections within the troves of clinical data, thereby offering invaluable insights into treatment effectiveness, patient demographic trends, and prospective adverse effects. For instance, AI applications can efficiently identify recurrent anomalies such as duplicate testing entries, gaps in patient reported outcomes (ePROs), data omissions, and medication inconsistencies. These insights enable AI to guide clinical data managers in formulating targeted queries to address observed discrepancies.

Moreover, AI algorithms are adept at enhancing the data preparation process, tackling tasks such as rectifying missing data, unifying disparate data formats, and excising statistical outliers[9]. This automated data refinement process not only conserves time but also guarantees the precision of the information. Beyond data sanitization, AI methodologies are capable of constructing predictive models from historical datasets, offering prognostications on patient groups' responses to treatment protocols. Such predictive modeling serves as a cornerstone for customizing trial design and intervention strategies for distinct patient demographics, there by advancing the personalization of patient care within clinical trials

3. Using AI to Transform Data

The Study Data Tabulation Model (SDTM) serves as a fundamental framework in the domain of clinical trials, structuring vast arrays of unrefined data into a coherent format that meets regulatory scrutiny. The increasing deluge of clinical trial data comprising patient records, laboratory results, image repositories, and sensory outputs aligns with the progression of technological capabilities, presenting a formidable onus upon researchers and statisticians to distill raw data into refined analytical and submission-ready forms.

Historically, the metamorphosis of raw clinical data into an SDTM-compliant structure necessitated extensive manual intervention. Researchers were tasked with the meticulous extraction, cleansing, and formatting of data, which proved to be both arduous and prone to protracted timelines. This conventionally slow and meticulous process was susceptible to human errors, often leading to data inaccuracies that could compromise trial integrity and delay regulatory approvals.

Enter the era of artificial intelligence (AI) where algorithms are engineered to emulate the cognitive functions of human intelligence in data transformation. AI's ability to rapidly process

and transmute data into an SDTM format revolutionizes the traditional paradigm[10]. It empowers trials with the swiftness of automation, drastically condensing the duration of data processing from weeks to days, and ensuring a high fidelity of data quality that aligns with stringent regulatory standards.

For instance, the SDTM conversion process, which historically could extend over seven to ten weeks with substantial manual labor, is now telescoped to approximately two weeks when AI automation is employed. This not only represents a substantial reduction in the labor hours from upwards of 800 hours down to roughly 80 but it also significantly decreases the human resource allocation to potentially just a single full-time employee.

Practical applications of AI in SDTM automation manifest in various aspects:

Speedy Transformation: AI algorithms swiftly convert diverse data forms into the structured SDTM format, facilitating quicker trial progression and decision-making.

Enhanced Accuracy: Automated checks and balances inherent in AI algorithms minimize human error, enhancing the integrity and reliability of data.

Cost Efficiency: The diminished need for extensive manual labor reduces operational costs and reallocates human resources to more critical analytical roles.

Regulatory Compliance: AI ensures that the structured data complies with regulatory mandates, providing seamless integration into submission dossiers for health authorities.

Predictive Analysis: AI-driven SDTM formats enable predictive analytics, allowing researchers to forecast trial out comes and patient responses accurately.

In summary, the advent of AI in SDTM automation not only alleviates the burden of manual data transformation but also fortifies the accuracy, efficiency, and regulatory alignment of clinical trial data management. The integration of such advanced automation paves the way for a more dynamic, responsive, and cost-effective clinical trial environment, primed for the challenges of modern medicine and research.

4. Conclusion

The voluminous influx of data within contemporary clinical trial databases has rendered the integration of Artificial Intelligence (AI) not just beneficial but paramount. The deluge of data generated overwhelms conventional manual processes, necessitating a more innovative approach. However, AI should not be misconstrued as a mere surrogate for these processes. Rather, it should be recognized for its potential to complement and enhance the efficiencies of traditional methods. By facilitating the prediction of patient behaviors-such as dropout rates, medication adherence, and the occurrence of adverse events-AI contributes significantly to the streamlined management of trials, thereby curtailing costs and bolstering patient outcomes.

AI's preeminence in clinical research is underscored by its capacity to expedite the analysis of data, without compromising on accuracy or depth, even as the quantity of data points surges. The adoption of AI tools is critical for researchers to swiftly identify and mitigate patient risks, thereby under pinning informed decision making and timely interventions to safeguard patient health.

Presently, a plethora of AI-driven solutions is readily accessible, offering researchers the tools necessary to distill valuable and actionable insights from the expansive and intricate data within clinical trials. Now is the opportune moment for trailblazers in the field to harness these powerful instruments, ensuring that modern clinical trials not only adhere to safety protocols but also operate with heightened efficiency.

5. References

1. https://www.drugdiscoverynews.com
2. RB Ghooi. Trials and tribulations of clinical research teaching and training. Perspect Clin Res, 2010; 1: 139-142.
3. V. P. Sriram, A. Mathur, J. Catherene, C. Aarthy, B. Basumatary, P. Mamgain, and H. Pallathadka. 2021; 3980-3992.
4. V Anisimov, S Gormley, R Baverstock, et al. Advanced models for predicting event occurrence in event-driven clinical trials accounting for patient dropout, cure and ongoing recruitment. *Arxiv Res*, 2021.
5. EE Bain, L Shafner, DP Walling, et al. Use of a novel artificial intelligence platform on mobile devices to assess dosing compliance in a phase 2 clinical trial in subjects with schizophrenia. *JMIR Mhealth Uhealth*, 2017; 5): 18.
6. T Ménard, Y Barmaz, B Koneswarakantha, et al. Enabling data-driven clinical quality assurance: Predicting adverse event reporting in clinical trials using machine learning. *Drug safety*, 2019; 42: 1045-1053.
7. U Mahmood, R Shrestha, DBD Bates, L Mannelli, G Corrias, E Y Erdi, C Kanan, 2021.
8. S Aparicio, JT Aparicio, CJ Costa. Data Science and AI: Trends Analysis. In: *2019 14th Iberian Conference on Information Systems and Technologies (CISTI)*, 2019; 1-6.
9. A Zimek, P Filzmoser. There and back again: Outlier detection between statistical reasoning and data mining algorithms. WIREs, 2018; 8: 1280.
10. https://www.saama.com/streamlining-clinical-trials-with-ai/